Adding Peptides to an Aesthetic Clinic in the Philippines

This guide contains no clinical content, and the omissions are the point rather than a gap. You will not find here what any of these compounds is said to do in a person, what anyone might be given, how much, how often, or what results anyone reports. No indications, no protocols, no dose figures, no before and after framing, and no efficacy language.

That is not squeamishness. Under the framework FDA Philippines administers, the definition of a drug turns on what an article is intended for, so a page that described human use would be doing the exact thing that moves an unregistered research material into the regulated category. A supplier-adjacent site that published protocols for a clinic to follow would be handing that practice a liability dressed as a resource.

If you are looking for the clinical case for adding this line, it is not here and it should not come from us. It should come from your own reading of the primary literature and from your own counsel, and if neither of those produces one, that is an answer rather than a missing section.

The compounds in question are supplied as analytical grade peptide reference materials for laboratory research. That is the category, and it is a complete description rather than a euphemism for something else. They arrive as lyophilised powder in a sealed vial, batch numbered, requiring reconstitution with bacteriostatic water before they are liquid at all.

None of them is FDA Philippines approved for human use. That is a registration fact, not a quality judgement, and it applies across the category: the repair compounds, the growth hormone axis compounds, the mitochondrial and cosmetic compounds, and the research grade incretin analogs alike. A small number of related molecules exist separately as registered medicines in branded pen form, dispensed on prescription, and those are a different thing in a different system. Prescribing a registered medicine belongs with a licensed Philippine physician, and the existence of an approved pen extends nothing to the research vial.

What that means for a practice is that the reassurance structure you are used to is simply not present. There is no approved indication to work within, no regulator-reviewed label to read, no marketing authorisation holder, and no established professional route by which this material reaches a patient. Whatever you build in place of that, you are building yourself.

The individual compound pages on this site set out what each one is and what the published research covers, in research terms. Those are the right pages for the science. This one is about what carrying the category does to a practice.

Most aesthetic practices in the Philippines already hold refrigerated injectables, and the instinct is to slot this in beside them. Operationally that instinct is half right. Regulatorily it is the source of most of the trouble.

The last row is the one to sit with. Every other difference has a workaround: you can run a tighter cold chain, you can build your own receiving record, you can hold batch numbers carefully. There is no operational answer to the last row. It is a decision, and it is the practice’s decision.

The reconstitution row deserves a practical note too, because it is the one that changes daily work. A lyophilised vial is stable in a way a reconstituted one is not, which means the moment of preparation is the moment your handling standard starts to matter, and it introduces a step your staff do not currently perform on anything else in the fridge.

A reseller ships a vial. A clinic administers, or supervises the administration of, an unapproved compound to a patient in a licensed facility, under a practitioner’s name. Those are not the same exposure and it is worth being blunt that the second is considerably larger.

Three layers stack on a practice that do not apply to someone shipping product. Professional regulation attaches to the practitioner rather than to the business. Facility regulation attaches to the premises and to what is done inside them. And consent is a live issue in a way it never is for a reseller: a patient consenting to something has to be consenting to what it actually is, which includes the fact that it is not an approved product and that nobody has assessed it for this use.

Underneath all three sits the same product question every seller in this market faces. The compounds are unregistered. The framework prohibits the sale, offering for sale, distribution, promotion and advertising of a health product that requires registration and is not registered, and it defines a drug by what an article is intended for rather than by what it is made of. A clinic that administers a compound to a person, and describes it to that person as doing something, has supplied both halves of that definition. The full treatment of the framework is in the regulatory guide, which is worth reading before this page goes any further for you.

A practice administering unapproved compounds is making its own regulatory decision. That sentence is the honest centre of this page. It is not a decision a supplier makes for you, it is not covered by a disclaimer you inherited from a supplier’s website, and it does not become safer because other clinics in your city are visibly doing the same thing. It is yours, it stays yours, and it should be taken with a Philippine lawyer who has looked at your specific practice before any stock is ordered.

If the regulatory question is settled and you are looking at operations, inventory behaves differently in a clinic than it does for a reseller, mostly in your favour.

A reseller guesses at demand across a whole market. A practice sees its own appointment book, which means demand is far more predictable and a narrow, shallow holding is usually the right shape. The failure mode is the same in both cases and it is breadth: carrying a little of many things because each looked worth having, then discovering that most of it moves slowly and all of it is occupying the fridge.

Two clinic-specific points are worth planning for. The first is that a practice cannot easily run out mid-course in the way a reseller can shrug off, because the person waiting is your patient and is sitting in your appointment book. That pushes toward holding depth on very few things rather than breadth on many. The second is that stock in a clinic has more people near it than stock in a reseller’s fridge, which is a control problem before it is a storage problem.

The capital arithmetic behind holding rather than ordering against confirmed demand is worked through in full on the startup cost guide. The same trade applies to a practice: depth is cheaper per vial and heavier on committed capital, and dead stock is the cost nobody budgets for.

Supply-side stock is held at 2 to 8°C and packed cold for transit. From the moment a box is opened in your practice, the chain is yours, and a clinic is held to a higher standard here than an individual buyer for the obvious reason that the material is going into someone who trusted your premises.

What that looks like in practice is unglamorous and familiar: a dedicated unit rather than a shared one, a monitored and recorded temperature rather than an assumed one, restricted access, and a written receiving check when a delivery lands. If you already run cold chain for other refrigerated stock, this is the same discipline extended rather than a new system. If you do not, this is not the category to learn on.

The Philippine ambient environment is the background condition that makes all of this less forgiving than the equivalent in a temperate country. Heat and humidity are the default rather than the exception, and a power interruption is a normal event rather than an emergency. Plan for both as routine, not as incidents.

One additional point specific to this category: because nobody has assessed the material for use in a person, a storage lapse has no safety net behind it. There is no stability data reviewed by a regulator to fall back on and no approved shelf life to consult. A gap in the chain is simply a gap, and the honest response to one is to stop using the material rather than to reason about it.

Two separate staff questions sit inside this, and practices reliably plan for the first and forget the second.

The first is physical handling. A named person receives, checks and records stock. Access is restricted rather than open. Reconstitution, if it happens on site, is performed by someone trained to do it and recorded when it is done, because a reconstituted vial is a different object from the sealed one and its history matters from that point. None of this is exotic, and any practice already running a controlled fridge will recognise all of it.

The second is what people are permitted to say. Front-of-house staff field questions all day, and a receptionist who tells a patient what a compound does has made a representation on behalf of the practice about an unapproved product. That is a real exposure created by an ordinary, well-meant conversation. A practice carrying this category needs an explicit position on which questions reception answers, which get routed to a practitioner, and what nobody says at all.

The same applies to your marketing, and more sharply. Promotion and advertising sit in the prohibition language alongside sale, so the marketing is a regulated act in itself. A post can therefore create exposure with no appointment booked from it. A practice that has thought carefully about its consent process and not at all about its Instagram has protected the smaller of the two surfaces.

Operationally, supply in this market is simpler than most practice managers expect and less formal than most would prefer.

Stock held inside the Philippines removes the part that makes overseas sourcing unworkable for a clinic: there is no customs leg, so restocking is a courier run rather than an import cycle you cannot schedule around. On the published terms, Metro Manila orders confirmed before 12 noon on a weekday go out same day, the rest of the country is 1 to 3 business days, and metro courier is free above ₱10,000. Every order ships with bacteriostatic water, insulin syringes, alcohol pads, a reconstitution syringe and blank labels, included rather than sold separately. Those figures were read from the published page on 9 September 2026.

What is less formal is the commercial side. There is no account portal, no published rate card past the pack sizes on the public page, and no purchase order system. Ordering runs through a WhatsApp thread, and terms for a practice are set per account in that conversation rather than published anywhere. For a practice manager used to distributor paperwork this is the adjustment, and it is worth deciding early whether your own record keeping can live with it, because your audit trail will be whatever you build rather than whatever the supplier sends.

One thing you should not expect to receive, and should be suspicious of if you are offered it: documentation asserting that material has been tested or certified to a purity standard. Where our partner and supplier stands is a dated statement from its own trust page: As of 12 September 2026, Primara Labs states that independent testing is in progress with two laboratories it names on its own trust page and that certificates will be published per batch. No certificate has been published yet. A practice whose consent conversation depends on producing a certificate should read that page for the batch it holds before relying on one. If another supplier hands you documents, read them properly and check what they actually say rather than what the covering message implies.

If you are still reading, these are the questions worth having answers to before any stock is ordered. They are ordered deliberately: the first three decide whether the rest are worth asking.

• What has your own lawyer said, in writing, about this practice administering unapproved compounds in this facility? Not a supplier’s position, not a peer’s reassurance. Yours.
• What does your consent process say, and does it state plainly that the material is not an approved product and that nobody has assessed it for this use? If a patient would be surprised by that sentence, the consent is not doing its job.
• Which practitioner’s name is on this, and have they agreed to that in full knowledge of the position rather than in passing?
• Who owns the fridge, who records the temperature, and what happens on the day the power goes out and nobody notices until the afternoon?
• What is reception allowed to say, and has anyone actually told them?
• What does your marketing not say, and who checks a post before it goes out?
• What happens when you run out and a patient is waiting? A reseller loses a customer. You have a different problem.

A page written by a supplier-adjacent site owes you this section more than any other, so here it is plainly.

Do not do this if the appeal is commercial and the regulatory question is something you intend to look at later. The sequence matters and reversing it is the single most common way practices get into difficulty with this category.

Do not do this if your practice does not already run a controlled cold chain competently. This is the wrong material to build that discipline on, because the consequences of a gap are unbounded in a way they are not for stock that has a reviewed shelf life behind it.

Do not do this if the line only pays when you describe what it does for a patient. A practice that needs the claim to fill the appointment is a practice whose business case and whose regulatory position point in opposite directions, and that tension does not resolve itself. It arrives every time the diary looks thin.

Do not do this if you want a supplier to carry the decision. Nobody will, and a supplier who says otherwise is either mistaken or selling you something. The practice carries it.

And do not do this because a competitor down the road has. What other clinics are visibly doing is information about the enforcement environment, not about whether the thing is sound, and enforcement environments change faster than clinics adapt.